Reports Q3 revenue EUR 57.84M vs. EUR 48.03M last year. “2024 has been another transformative year for Ascendis. Now, all three of our three endocrinology rare disease programs have delivered clinically differentiated pivotal data, each demonstrating potential ability to address major unmet medical needs and the potential for each to achieve blockbuster status. We are ready and very excited about launching YORVIPATH in the U.S. with product availability expected in mid-January of 2025,” said Jan Mikkelsen, Ascendis Pharma’s (ASND) President and Chief Executive Officer. “In addition, our new partnership with Novo Nordisk highlights our ability to extend the success of our TransCon platform and positions Ascendis to benefit patients and capture significant value in this large, high volume therapeutic areas.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ASND:
- Ascendis Pharma Expands Capital to Fuel Growth
- Ascendis Pharma and Novo Nordisk Join Forces
- Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform
- Ascendis Pharma A/S (ASND) Q3 Earnings Cheat Sheet
- BioMarin price target lowered to $90 from $110 at Cantor Fitzgerald
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
